When Prof James Brenton was seeing one of his patients at Addenbrooke's recently for ovarian cancer treatment, he needed to review all her studies and treatments. The information was complex and lengthy: blood test results, genomic tests, imaging studies and reports from past therapy. Brenton hadn’t been able to attend the tumour board meeting the day before, where his colleagues — radiation oncologists, medical oncologists, radiologists, pathologists and surgeons — had reviewed her data. The recap from the meeting was helpful, but overly brief. Brenton sorted through the medical information available electronically, repeatedly switching from one source of information to another.
This scenario plays out every day in clinics across the UK and around the world. What would help Brenton, a medical oncologist and co-leader of the Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge, is a single digital location that offers cancer care teams access to data from multiple systems in one view and via a single interface for ease of use. This would help clinicians make personalised treatment decisions for each patient’s cancer journey.
The good news is that the solution to these problems is in development. The University of Cambridge, and Addenbrooke’s Hospital are collaborating with GE Healthcare to make this possible by providing clinical expertise, data and evaluation of the application. Brenton and the other collaborators from MFICM and the Cancer Research UK Cambridge Centre hope to make digitally integrated cancer medicine available to clinicians across the UK, from diagnosis through each stage of treatment.
Brenton and Professor Evis Sala, a professor of oncological imaging at the University of Cambridge and co-leader of the MFICM are confident in the concept. They’ve independently created a data integration framework and an algorithm for ovarian cancer data, then hit a wall trying to implement it in clinical practice. “In academia, we’re very good at the innovation part and doing it small scale in a controlled research environment,” says Sala.
What will the GE Edison platform do?
The GE Edison Health Services platform is designed to integrate and aggregate data from multiple and diverse sources, including electronic health records (EHR), radiology information systems (RIS), medical device data, and laboratory and genomic results. With this project, data from multiple sources will be brought together making it easy to access all patient information – such as scans, clinical records and genetic results – from the same place at the same time.
Edison Health Services is also designed to host and orchestrate the deployment of Artificial Intelligence (AI) algorithms relevant to a given portion of the workflow. These AI-enabled algorithms can for instance be used with the integrated data to help refine and explain complicated patient data, to help a clinician compare a patient’s information to other patients with cancer, and to present the information visually to the clinician. AI analysis and algorithms could also be designed to bring additional insights to the clinician through radiomics, such as segmenting imaging studies to auto-quantify tumour sizes and tissue borders (the thin line where cancer cells meet normal tissue) and showing other imaging patterns the human eye can’t detect.
These types of AI algorithms may allow the clinician to spend less time and manual labour in order to identify tissue borders, for example, and more time on higher level patient care. Clinically verified algorithms have the potential to raise the standard of care by sharing treatment expertise with general oncologists, which is particularly useful when treating many cancer types.
It starts with ovarian cancer
The collaboration will initially focus on ovarian cancer, partly because Brenton and Sala have significant experience in this area. But it is also addressing an unmet need. “Ovarian cancer is a relatively underfunded cancer with poor outcomes, and we need new systems to deal with its complexity,” Brenton says. Ovarian cancer lags behind some of the advances made in other cancers, like breast cancer, in treatments and outcomes.
Given the rarity of ovarian cancer, expertise treating it is not widespread in all UK community hospitals, says Brenton. If this collaboration works well, the Edison Health Services platform may help clinicians bring a higher level of care to patients in additional clinical oncology locations.
Ovarian cancer is the first disease that the collaboration will take on, and the collaborators hope that the project can be scaled to other cancer pathways in the near future.
Brenton adds: “By working with GE Healthcare we will greatly benefit from their business and software engineering skills, and their ability to work with other technologies to build solutions that we can then add value to. We are all tremendously excited about bringing these advances to patients to improve their care. This is a game-changing initiative that will help ensure rapid translation of our research into patient care.”